TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
Enrolling By Invitation
18 years - 99 years
All
Phase
4
5 participants needed
1 Location
Brief description of study
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine any changes in your health or side effects occurring within 24 hours following treatment with TEGSEDI.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: hATTR-PN
-
Age: 18 years - 99 years
-
Gender: All
Male or Female Age 18 or older Diagnosis of hATTR-PN
Updated on
04 Aug 2024.
Study ID: TEG4004
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
